US cosmetic and personal care companies anticipating potential tariffs are concerned over a variety of “turnkey products, packaging components and ingredients” for cosmetics sourced from Asia and in particular, China, according to Akemi Ooka, VP of global supply chain and sustainability resources, at the Independent Beauty Association.
Cosmetic Industry Braces For Looming Tariffs, With Eye On Asian Botanicals
With Trump administration tariffs effective possibly within days, US cosmetic and personal care companies are concerned about the impact of both cost and supply for ‘turnkey’ products, packaging components and ingredients from Asia, in particular China.
More from Policy & Regulation
• By
Data from the US Food and Drug Administration indicated that two hair dye ingredients are formulated in eye makeup and dermal application products, prompting a Cosmetic Ingredient Review panel to conclude one dye is unsafe for such uses and discouraging those uses in the other dye.
• By
Preliminary registration data released by FDA offers a first glimpse of the Modernization of Cosmetics Regulation Act’s impact on information the agency has at hand.
• By
Counterfeit beauty products cost the US industry an estimated $3bn in 2023, says a trade expert during the Personal Care Products Council’s Beauty Collective Summit.
• By
Cosmetic companies should conduct audits to identify products that will be required to disclose fragrance allergens and begin the work of adjusting labels, particularly for smaller packaging, says a director at Registrar Corp., during a 12 March webinar on MoCRA and labeling.
More from HBW Insight
• By
Kim Kardashian lifestyle company SKIMS buys back rights to SKKN by Kim from Coty, Inc., which had purchased a 20% interest in the brand in 2020 for $200m. Separately, NYX Professional Makeup partners with Warner Bros. to launch the “A Minecraft Movie” collection.
• By
Chinese consumers are now routinely taking supplements for a variety of health reasons, helping to drive up sales of the Swisse Plus+ brand by 20% in 2024.
• By
US FDA Commissioner nominee Martin Makary is being embraced by industry, and Senate Democrats, as a more traditional pick than other Trump Administration nominees, but the Make America Healthy Again agenda still is clearly coming to the agency.